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To evaluate the reliability of using in situ frog intestinal perfusion technique for
permeability assessment of carrier transported drugs which are also substrates for CYP
enzymes. Single Pass Intestinal Perfusion (SPIP) studies were performed in frogs of the
species Rana tigrina using established method for rats with some modifications after
inducing anesthesia. Effective permeability coefficient (Peff) of losartan and midazolam
was calculated in the presence and absence of inhibitors using the parallel-tube model.
Peff of losartan when perfused alone was found to be 0.427 ± 0.27 × 10−4cm/s and
when it was co-perfused with inhibitors, significant change in Peff was observed. Peff
of midazolam when perfused alone was found to be 2.03 ± 0.07 × 10−4cm/s and
when it was co-perfused with inhibitors, no significant change in Peff was observed.
Comparison of Peff calculated in frog with that of other available models and also
humans suggested that the Peff-values are comparable and reflected well with human
intestinal permeability. It is possible to determine the Peff-value for compounds which
are dual substrates of P-glycoprotein and CYP3A4 using in situ frog intestinal perfusion
technique. The calculated Peff-values correlated well with reported Peff-values of probe
drugs. comparison of the Peff-value of losartan obtained with that of reported human’s
Peff and Caco 2 cell data, and comparison of the Peff-value of midazolam with that
of reported rat’s Peff, we could conclude that SPIP from model can be reliably used
in preclinical studies for permeability estimation. This model may represent a valuable
alternative to the low speed and high cost of conventional animal models (typically
rodents) for the assessment of intestinal permeability.
Keywords: effective permeability coefficient, single pass intestinal perfusion, P-glycoprotein, CYP3A4, frog
intestinal perfusion, in situ models for drug permeability assessment, P-gp CYP3A interaction studies
Introduction
In order to bring safe and eﬀective drugs to the market it is crucial to understand the factors
inﬂuencing drug absorption and predict these values on the basis of pre-clinical in vitro and/or
in situ experiments (Lipka and Amidon, 1999). Drug absorption across the intestinal membrane
is a culmination of complex processes. Passive absorption takes place by transcellular route
(through the cell membrane of enterocytes) or by Para cellular route (through the tight junctions
between the enterocytes). Active absorption occurs by carrier mediated transport or facilitated
diﬀusion. “Various eﬄux transporters such as P-gp, BCRP, MRP2 are also present that might
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pump the drug back, thus limiting the absorption. Intestinal
enzymes present metabolize drugs to alternate moieties” (Kim
et al., 1995). Multivariate processes are involved in intestinal
absorption of drugs. Hence it is diﬃcult to use a single model to
accurately predict the in vivo permeability characteristics of drug
candidates.
Metabolism by cytochrome P4503A4, the major isoform of
CYP3A subfamily, and mdr1 P-glycoprotein (P-gp), an ATP-
binding cassette transmembrane transporter (ABC transporter)
mediated eﬄux act as two important rate limiting biological
barriers to drug absorption from the intestine. It is well
documented that the metabolism/active eﬄux in the small
intestine is involved in the poor bioavailability of many drugs
(Krishna and Koltz, 1994; Cécile et al., 2007). CYP3A4 is
mainly expressed in liver, but intestinal enterocytes also express
considerable amounts of CYP3A4, substantial enough to alter
bioavailability of many marketed drugs (Paine et al., 1997; Von
Richter et al., 2004). P-glycoprotein is also expressed on the
brush border membrane of enterocytes. The substrate speciﬁcity
of CYP3A and P-gp overlap each other. As a result these
two proteins act synergistically in reducing the bioavailability
of their substrates after oral administration (Thummel et al.,
1997; Ambudkar et al., 1999). Many drug–drug or drug–
food interactions in preclinical and clinical studies have been
associated with transporter mediated eﬄux (Varma et al., 2006).
Hence it is essential to screen molecules for P-gp involvement
during preclinical studies.
Several in vitro, in vivo, and in situ techniques have been
reported for permeability studies involving P-gp and also CYP3A.
In vitro models include cell lines which over-express P-gp
(MDCK, Caco-2) either cDNA transfectants over expressing P-gp
or non-transfected cell lines and also the ex vivo Using Chamber
model using excised rat intestinal Segments (Tukker, 2000).
Though in vitro techniques have the advantage of generating
large volumes of data, they are not thoroughly standardized and
are associated with several limitations, hence less predictive. The
Caco-2 cell model is routinely used to investigate drug transport
because of its structural and physiological similarity to the
intestinal epithelium, including the expression of P-gp (Balimane
and Chong, 2005). However, quiescent Caco- 2 cells do not
normally express CYP3A4 and also they do not always express
appropriate amounts of transporters or enzymes (Artursson and
Karlsson, 1991).
In situ single pass intestinal perfusion (SPIP) technique using
diﬀerent animal species including rat, rabbit, pig, dog, and
monkey has been reported in literature to study the intestinal
absorption of drugs. Among these animal models, SPIP in rat
is a well-established technique to study the intestinal passive
absorption of drugs with good correlation between human
and rat intestinal absorption but for drugs whose intestinal
permeability is driven by carrier-mediated absorption this is not
the case. “Expression proﬁles of transporters and metabolizing
enzymes in both rat and human intestines (duodenum and
colon) were measured using Gene Chip analysis. There was no
correlation between rat and humans (r2 = 0.29) in oral drug
bioavailability, which also agreed with previous results” (Cao
et al., 2006). Hence there is a clear need for the development
of a novel model for the study of intestinal absorption of drugs
involving transporters such as P-gp and CYP3A enzymes.
In this study we have developed SPIP using frog as the animal
model for the assessment of intestinal permeability of drugs,
which are substrates of P-gp, and CYP3A4 in humans. Frog
small intestine has the same composition and villi as vertebrate
membranes and same transport mechanisms and luminal
enzymes have evolved from lower vertebrates to humans. This
is further supported by a study, in which in vitro permeability
coeﬃcient deduced from isolated frog intestinal sac showed to
be a reasonable predictor of in vivo oral absorption in humans
for compounds that are passively absorbed (Trapani et al.,
2004). Another study also indicated the expression of speciﬁc
transporter systems in frog intestine (Franco et al., 2008). When
compared with in vitro methods, SPIP provides an advantage
of experimental control (e.g., permeate concentration, intestinal
perfusion rate), intact intestinal blood supply, and barrier
function of the intestine is not lost or compromised during the
entire length of the experiment (Lennernäs, 2007). Tissue viability
is much longer when compared with in vitro isolated intestinal
segment models. In a study, we have demonstrated that the SPIP
frog model can be used for the biopharmaceutical classiﬁcation
(Yerasi et al., 2015).
The objective of the present study was to evaluate the
reliability of using in situ frog intestinal perfusion technique
for permeability assessment of carrier transported drugs, which
are also substrates for CYP3A4 enzymes. We have chosen the
antihypertensive drug losartan as one of the probe drugs since
it exhibits highly variable and low oral bioavailability (Lo et al.,
1995). Losartan is a CYP3A4 substrate, which undergoes phase-1
metabolism in the intestine and active secretion in to the lumen
by P-gp after absorption (Benet et al., 1996; Borst et al., 1997).
The second probe drug is midazolam, a general anesthetic agent,
which is a speciﬁc probe used for assessing the metabolic activity
of the CYP3A4/1 enzymes and it is not a substrate for P-gp
(Takano et al., 1998; Fromm, 2004; Cécile et al., 2007).
Materials and Methods
Materials
Losartan, verapamil, and ritonavir pure substances were obtained
as gift samples from Dr Reddy’s Laboratories, Hyderabad,
India. Cyclosporine A was obtained as gift sample from Bharat
Serums limited, Mumbai, India. Midazolam and ketoconazole
pure substances were obtained as gift samples from Lupin
Laboratories, Pune, India. All the solvents were of HPLC
grade obtained from Rankem India. Potassium dihydrogen
orthophosphate, orthophosphoric acid was purchased from E.
Merck Limited, Mumbai, India and all other chemicals were
obtained from Hi Media, Mumbai, India.
Composition of Perfusion Solutions
The perfusion buﬀer composition was as follows: CaCl2 × 2H2O,
0.98 mM, KCl 2.58 mM, Na2HPO4 0.66 mM, NaH2PO4 5.1 mM,
NaCl 84 mM, D-glucose 3.0 mM with pH 6.8 (with NaOH)
phenol red (50 mg L−1) was added to the solution as a
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non-absorbable marker. The pH was adjusted to 7.4 and the
osmolality, measured by the freezing point depression method,
was 230 ± 10 mOsm kg−1 (Osmette A, Precision Systems Inc.,
Natick, MA, USA) isotonic for amphibian (Franco et al., 2008).
Preliminary experiments showed that there was no adsorption
of the compounds to the catheters and the tubing. Test drug
concentrations used in the perfusion studies were selected
by dividing the maximum prescribed dose of the drug by
250 ml, the accepted gastric volume, so as to represent maximal
concentration in the intestinal segment. Solutions of probe drugs
were prepared with blank perfusion buﬀer. Probe drugs and
inhibitors used in the study, if insoluble in perfusion buﬀer were
solubilized using less than 1% methanol.
Analytical Methods
Samples were analyzed by reverse-phase HPLC. A liquid
chromatographic system (HPLC; Agilent) with a solvent pump
(Agilent 1100 binary pump) and UV-vis multiple wavelength
detector (MWD-G1365B, was used. Chemstation R©software was
used for data acquisition, reporting, and analysis. The C-18
reverse phase column used for chromatographic separation
was Zorbax (particle size 5 μ, pore size 10 nm, dimension
FIGURE 1 | Representative chromatogram of a sample from intestinal perfusion containing losartan and phenol red.
FIGURE 2 | Representative chromatogram of a sample from intestinal perfusion containing midazolam and phenol red.
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TABLE 1 | Effective permeability coefficient (10−4cm s−1) of losartan and
Midazolam.
Frog Human Rat Caco-2
Losartan 0.427 ± 0.27 1.15a ∗ 0.022b
Midazolam 2.03 ± 0.07 ∗ 2.08 ± 0.50c ∗
Values are mean ± SD of six values.
aLennernäs, 2007.
bAndrea et al., 2000.
cCécile et al., 2007.
FIGURE 3 | Effective permeability coefficient of losartan in presence of
Cyclosporine, Verapamil, Ketoconazole, Ritonavir, and also
combination of Cyclosporine and ketoconazole at 1, 10, 30, 50 µM,
respectively.
4.6 mm × 250 mm) of Agilent technologies. Mass spectral
analysis of the perfusates, wherever required was done by Agilent
LC-MSD ion trap in positive ion mode.
Chromatographic Conditions
For losartan, the mobile phase was a mixture of 50% acetonitrile,
50% 0.05 M Phosphate buﬀer (Potassium dihydrogen phosphate,
(pH adjusted to 3.2 with ortho phosphoric acid) and 0.5%
triethylamine. For midazolam the mobile phase was a mixture
of 0.05 M phosphate buﬀer (pH adjusted to 3.5 with
orthophosphoric acid) and acetonitrile (65:35). The mobile phase
was ﬁltered through sintered glass ﬁlter P5 (1–1.6 μm; Winteg,
Germany) and degassed in sonicator (Liarre, Italy). The mobile
phase was pumped in isocratic mode at a ﬂow rate of 1ml/min at
ambient temperature for both the drugs. The UV detection was
accomplished at 250 nm for losartan and 254 nm for midazolam.
Quantiﬁcation of the compounds was carried out by measuring
the peak areas in relation to those of standards chromatographed
under the same conditions.
Frog In-Situ SPIP Technique
Frog in situ perfusion studies were performed using established
SPIP method for rats (Varma and Panchagnula, 2005) with
few modiﬁcations. Animal care and handling throughout the
experimental procedure were performed in accordance with the
FIGURE 4 | Effective permeability coefficient of midazolam in presence
of Cyclosporine, Verapamil, Ketoconazole, Ritonavir, and also
combination of Cyclosporine and ketoconazole at 1, 10, 30, 50 µM,
respectively.
“Principles of Laboratory Animal Care” (NIH publication #85–
23, revised in 1985). Frogs of the species Rana tigrina, were used
for the experiments. Frogs were fasted for 24 h prior to the start
of the experiment. Each frog was anesthetized and maintained
with a combination of intra-peritoneal injection of 230 mg/kg of
phenobarbitone sodium and 25 mg/kg of thiopentone sodium.
After the onset of deep anesthesia, abdomen was opened by
a midline longitudinal incision, and approximately 15–20 cm
length of intestine immediately after stomach was selected, rinsed
with frog’s ringer and cannulated on both sides. Care was taken
in handling the small intestine to minimize the blood loss.
Initially the contents of the intestine were ﬂushed out with
blank perfusion solution, then with the test solution, and then
perfused with test solutions at a ﬂow rate of 0.2 ml/min using
syringe pump for 90 min after 30 min of equilibration. The
perfusate samples were collected at every 10 min. Water ﬂux
was quantiﬁed with the help of concentration change of phenol
red (non-absorbable inert marker). The length and radius of the
perfused segment was measured at the end of the experiment
and the animal was euthanized by quick removal of the heart.
Permeability for each drug with or without inhibitor at diﬀerent
concentrations was determined in six frogs and the results were
presented as mean ± SD. Samples were stored at −20◦C until
analysis. Eﬀective permeability coeﬃcient (Peﬀ) of Losartan and
Midazolam at concentrations 20, 40 mM, respectively, were
calculated alone and also in presence of inhibitors of P-gp and/or
CYP3A4 such as cyclosporine, verapamil, ketoconazole, ritonavir,
and also combination of cyclosporine and ketoconazole each at
increasing concentrations 1, 10, 30, 50 μM, respectively.
Data Analysis
Effective Permeability Coefficient (Peff)
Eﬀective permeability coeﬃcient (Peﬀ) was calculated from
the steady-state concentration of compounds in the collected
perfusate (Komiya et al., 1980). Steady state, which was assessed
by a constant concentration of phenol red, was reached
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TABLE 2 | Effective permeability coefficient (10−4cm s−1) of losartan in
presence of inhibitors.
Inhibitors 1 µM 10 µM 30 µM 50 µM
Cyclosporine 0.38 ± 0.07 0.63 ± 0.12 4.80 ± 0.13 4.60 ± 0.04
Verapamil 0.44 ± 0.09 0.48 ± 0.02 0.70 ± 0.16 2.90 ± 0.14
Ketoconazole 0.43 ± 0.04 0.47 ± 0.13 0.35 ± 0.14 0.17 ± 0.03
Ritonavir 0.42 ± 0.05 0.79 ± 0.09 0.79 ± 0.17 3.60 ± 0.14
Cyclosporine
+Ketoconazole
0.39 ± 0.02 0.88 ± 0.15 1.80 ± 0.18 1.20 ± 0.16
∗Values are mean ± SD of six values.
TABLE 3 | Effective permeability coefficient (10−4cm s−1) of Midazolam in
presence of inhibitors.
Inhibitors 1 µM 10 µM 30 µM 50 µM
Cyclosporine 2.1 ± 0.06 1.9 ± 0.05 2.12 ± 0.14 2.07 ± 0.03
Verapamil 2.07 ± 0.12 2.03 ± 0.06 2.21 ± 0.05 2.09 ± 0.05
Ketoconazole 1.83 ± 0.11 1.89 ± 0.02 0.45 ± 0.08 0.47 ± 0.05
Ritonavir 1.90 ± 0.14 1.70 ± 0.09 0.31 ± 0.02 0.33 ± 0.08
Cyclosporine +
Ketoconazole
1.84 ± 0.13 1.87 ± 0.03 0.41 ± 0.04 0.45 ± 0.03
∗Values are mean ± SD of six values.
30 ± 40 min after the beginning of the experiment. Peﬀ-value
was calculated using equation (1), according to the parallel tube
model (Sinko et al., 1991).
Peﬀ = −Q ln [Cout corr/Cin]/2πrl (1)
Where Q is perfusion ﬂow rate (ml/min). Cin is inlet
concentration (μg/ml). Cout(corr) is outlet concentration of
compound which is corrected for water ﬂux using phenol red
concentration (μg/ml) [Cout (corr) = Coutmeasured × (phenol red)
in/(phenol red) out], r is the radius of the frog intestine (cm). One
is the length of the intestinal segment (cm). The concentrations
obtained from the perfusate were corrected for changes in the
water ﬂux at each time interval using the above equation.
Results and Discussion
The eﬀective permeabilities (Peﬀ) were determined in frogs,
in situ, from steady state values of Cout corr/Cin, for losartan,
and midazolam. Steady state was attained in about 30–40 min,
after beginning of the perfusion. Compounds were perfused alone
and in presence of inhibitors to elucidate the role of P-gp and
CYP3A4. Equilibrium was reached within 30–40 min, as assessed
by the concentration of phenol red in the outlet. The recovery
of phenol red was 98.3 ± 1.0%, in agreement with previous
reports (Miller et al., 1987), indicating that the intestinal mucosa
was not altered during the procedure. Eﬀective permeability
coeﬃcient (Peﬀ) of losartan and midazolam were calculated alone
and also in the presence of cyclosporine and ritonavir which
are well known inhibitors of P-gp and CYP3A4 (Benet et al.,
2004). Cyclosporine and ritonavir were selected since they are
dual inhibitors and the change in Peﬀ of losartan in presence of
these inhibitors helps us to conclude the expression of P-gp and
CYP3A4 in frog intestine. The eﬀective permeability coeﬃcient
(Peﬀ) values were also determined at steady state in the presence
of ketoconazole, a CYP3A4 inhibitor, and verapamil, inhibitor of
P-gp. Ketoconazole was selected since it is a potent inhibitor of
CYP3A4 enzyme (Takahiro et al., 2002). Verapamil was selected
since it inhibits only P-gp but not CYP3A4 (Verschraagen et al.,
1999). Each inhibitor was tested for its inhibitory potential at four
diﬀerent concentrations to authenticate the results. Furthermore
cyclosporine being a potent inhibitor of P-gp and ketoconazole,
a potent inhibitor of CYP3A4 were used in combination at four
FIGURE 5 | Representative mass spectrum of a sample from intestinal perfusion containing peak corresponding to hydroxy midazolam.
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diﬀerent concentrations to determine their eﬀect on intestinal
permeability in frog.
The collected outlet perfusate samples were stored at −20◦C
until analysis and they were analyzed by established RPHPLC
methods from literature after optimization. In Figures 1 and 2
the representative chromatograms of phenol red, losartan, and
phenol red, midazolam are presented. There was no interference
from the inhibitors. The retention times were 4.0min and 5.2 min
for phenol red and losartan, respectively, and for midazolam and
phenol red they were 8.03 and 10.49min, respectively. Linearity
was found by the six-point calibration curves for phenol red
and losartan prepared in the range of 10–150 μg/ml. This
concentration range was selected based on drug concentration
used in permeability studies.
Eﬀective permeability coeﬃcient of losartan was found to
be 0.427 ± 0.27 × 10−4 cm/s when perfused alone and when
it was co-perfused with inhibitors, signiﬁcant change in Peﬀ
was observed. Similarly, eﬀective permeability coeﬃcient of
midazolam was found to be 2.03 ± 0.07 × 10−4 cm/s when
perfused alone and when it was co-perfused with inhibitors,
no signiﬁcant change in Peﬀ was observed. Comparison of
eﬀective permeability coeﬃcient of losartan and midazolam
in frog and other permeability models reported in literature
is given in Table 1. Comparison of eﬀective permeability
coeﬃcient of losartan and midazolam in frog in presence of
cyclosporine, ritonavir which are very well known inhibitors
of P-gp and CYP3A4, ketoconazole, a CYP3A4 inhibitor, and
verapamil, inhibitor of P-gp at four concentrations (1, 10, 30,
50 μM, respectively) and also cyclosporine and ketoconazole,
in combination (1:1) at these concentrations is depicted in
Figures 3 and 4. The data are shown in Tables 2 and 3. Signiﬁcant
increase in the eﬀective permeability coeﬃcient of losartan was
observed in the presence of cyclosporine at 30, 50 μm. 11.16-
fold increase in Peﬀ was observed at 30 μm concentration
and 10.70-fold increases in Peﬀ was observed at 50 μm
concentration. Signiﬁcant increase (8.37-fold increase) in the
eﬀective permeability coeﬃcient of losartan was observed in the
presence of ritonavir at 50 μm concentration. Verapamil showed
6.74-fold increase in eﬀective permeability coeﬃcient at 50 μm.
These values indicate that losartan is actively eﬄuxed by P-gp in
the frog intestine since eﬀective permeability coeﬃcient increased
signiﬁcantly in presence of known inhibitors of P-gp such as
cyclosporine, ritonavir, verapamil. In presence of ketoconazole
signiﬁcant change in eﬀective permeability coeﬃcient was not
observed but in presence of cyclosporine and ketoconazole, in
combination (1:1) at 30, 50 μM, respectively, showed signiﬁcant
change in eﬀective permeability coeﬃcient. Comparison of these
values with that in presence of cyclosporine alone indicate that
losartan is also metabolized probably by CYP3A4 enzymes or
other isoforms of CYP enzymes.
The eﬀective permeability coeﬃcient (Peﬀ) of midazolam
when perfused alone was found to be 2.03 ± 0.07 × 10−4cm/s.
Signiﬁcant change in eﬀective permeability coeﬃcient was not
observed as expected in presence of any of the inhibitors of
P-gp as it is well known that midazolam is not a substrate
for P-gp. Moderate change in eﬀective permeability coeﬃcient
was observed in presence of ketoconazole, a potent CYP3A4
inhibitor. This suggests that enzymes similar to CYP might have
been expressed in frog intestine. Moreover in a study several
new CYP1 genes were identiﬁed in vertebrates (chicken, Gallus
gallus, and frog, Xenopus tropicalis; Goldstone et al., 2007). In
another study it was demonstrated that it is possible to determine
the Peﬀ-value for compounds which are substrates of CYP3A4
using in situ frog intestinal perfusion technique (Yerasi et al.,
2010). To support this argument further, the perfusate samples
were analyzed by mass spectroscopy. Mass spectra of some of the
perfusate sample showed (M+H) peak, m/z 342 corresponding to
hydroxymidazolam exhibiting mass diﬀerence of M+17 against
the parent, the mass spectrum is shown in Figure 5. Comparison
of Peﬀ calculated in frog with that of other available models and
also humans suggested that the Peﬀ-values are comparable and
reﬂected well with human intestinal permeability. The Peﬀ of
midazolam calculated in rat everted gut sac model and frog was
found to be almost the same which is given in Table 1.
Comparision of the eﬀect of inhibitors on the observed
eﬀective permeability coeﬃcient (Peﬀ) of probe drugs requires the
understanding of physical model taken in to account to calculate
eﬀective permeability coeﬃcient. Of the two frequently used
mathematical models (Well stirred model, Parallel tube model)
to calculate Peﬀ, as stated earlier we have used parallel tube model
since it takes in to account water absorption and secretion in
to luminal drug solution in the intestinal segment. Considering
it as a cylindrical tube, Peﬀ calculated is inversely proportional
to Cref lumen which is approximated as the logarithmic mean
concentration (C) in the intestine [i.e., <C>=(Cout − Cin)/ln
(Cout/Cin)]. P-gp expressed on the brush border membrane of
enterocytes excretes its substrates into the lumen thus increasing
the substrate’s Cref lumen. So when P-gp is inhibited Cref lumen
decreases and Peﬀ increases, which are seen in case of probe
drug losartan in presence of P-gp inhibitors such as cyclosporine
and verapamil. CYP3A4 present in the gut wall metabolizes the
substrate drug thus decreasing the Cref lumen. So when CYP3A4
is inhibited Cref lumen increases and Peﬀ decreases, which is
seen in case of probe drug midazolam in presence of CYP3A4
inhibitors such as ketoconazole and ritonavir.
These results authenticate that P-gp and CYP3A enzymes
are expressed in frog intestine and hence frog intestinal model
can be reliably used as an animal model for studying intestinal
permeability of drugs especially drugs which are substrates for
P-gp and CYP enzymes. Further, comparison of the Peﬀ-value
of losartan obtained with that of reported human’s Peﬀ and
Caco-2 cell data, and comparison of the Peﬀ-value of midazolam
with that of reported rat’s Peﬀ, we can conclude that SPIP using
frog as animal model can be reliably used in preclinical studies
for permeability estimation. This model serves as a valuable
alternative for permeability estimation of drugs which are dual
substrates of P-gp and CYP3A4 since use of rat model and Caco-
2 cell line model for such drugs are associated with limitations,
though they are gold standards for permeability estimation of
passively absorbed drugs such as model being static, absence of
a mucus layer due to lack of mucous secreting cells, with diﬀerent
or no expression of metabolic enzymes (e.g., absence of CYPs),
“Tighter” monolayer compared to human small intestine, wide
Inter- and intra-laboratory variability of permeability data, Long
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diﬀerentiation period, Low expression of eﬄux transporters.
Limitations of rat model include diﬀerent expression proﬁles
of transporters and metabolizing enzymes when compared with
humans and the model is not suitable for high throughput
screening. The frog model reported here appears to be promising
for permeability assessment of drugs which are substrates for
eﬄux proteins and CYP3A enzymes.
Conclusion
Frog SPIP proves to be a promising model to calculate
permeability coeﬃcient of drugs which are substrates of P-gp
and/or CYP3A4. Since this model mimics in vivo situation, most
of the disadvantages of in vitro models are negated. It serves as a
cost eﬀective alternative to existing in situmodels.
References
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and
Gottesman, M. M. (1999). Biochemical, cellular, and pharmacological aspects
of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361–398. doi:
10.1146/annurev.pharmtox.39.1.361
Andrea, S., Benet, L. Z., Mutschler, E., and Christians, U. (2000). Active transport of
the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across
MDCK-MDR1 and Caco-2 cell monolayers. Br. J. Pharmacol. 129, 1235–1243.
doi: 10.1038/sj.bjp.0703150
Artursson, P, and Karlsson, J. (1991). Correlation between oral drug absorption
in humans and apparent drug permeability coeﬃcients in human intestinal
epithelia (Caco-2) cells. Biochem. Biophys. Res. Commun. 175, 880–890. doi:
10.1016/0006-291X(91)91647-U
Balimane, P. V., and Chong, S. (2005). Cell culture-based models for intestinal
permeability: a critique. Drug Discov. Today 10, 335–343. doi: 10.1016/S1359-
6446(04)03354-9
Benet, L. Z., Cummins, C. L., and Wu, C. Y. (2004). Unmasking the dynamic
interplay between eﬄux transporters andmetabolic enzymes. Int. J. Pharm. 277,
3–9. doi: 10.1016/j.ijpharm.2002.12.002
Benet, L. Z., Wu,C. Y., Hebert, M. F., and Wacher, V. J. (1996). Intestinal drug
metabolism and antitransport processes: a potential paradigm shift in oral
drug delivery. J. Control Release. 39, 139–143. doi: 10.1016/0168-3659(95)
00147-6
Borst, P., Kool, M., and Evers, R. (1997). Do cMOAT (MRP2), other MRP
homologues, and LRP play a role in MDR? Semin. Cancer Biol. 8, 205–213. doi:
10.1006/scbi.1997.0071
Cao, S. T., Gibbs, L., Fang, H. A., Miller, C. P., Landowski, H. C., Shin, H., et al.
(2006). Why is it challenging to predict intestinal drug absorption and oral
bioavailability in human using rat model. Pharm. Res. 23, 1675–1686. doi:
10.1007/s11095-006-9041-2
Cécile, A., Claude, P., Christelle, V., John, W., and Georges, H. (2007). The
metabolism of midazolam and comparison with other CYP enzyme substrates
during intestinal absorption: in vitro studies with rat everted gut sacs. J. Pharm.
Pharmaceut Sci. 10, 26–36.
Franco, M., Lopedota, A., Trapani, A., Cutrignelli, A., Meleleo, D., Micelli, S., et al.
(2008). Frog intestinal sac as an in vitro method for the assessment of intestinal
permeability in humans: application to carrier transported drugs. Int. J. Pharm.
352,182–188. doi: 10.1016/j.ijpharm.2007.10.027
Fromm,M. F. (2004). Importance of P-glycoprotein at blood-tissue barriers.Trends
Pharmacol. Sci. 25, 423–429. doi: 10.1016/j.tips.2004.06.002
Goldstone, J. V., Goldstone, H. M. H., Morrison, A. M., Tarrant, A., Kern, S. E.,
Woodin, B. R., et al. (2007). Cytochrome P450 1 genes in early deuterostomes
(Tunicates and Sea Urchins) and vertebrates (Chicken and Frog): origin and
diversiﬁcation of the CYP1 gene family. Mol. Biol. Evol. 24, 2619–2631. doi:
10.1093/molbev/msm200
Kim, R., Wendel, C., Leake, B., Cvetkovic, M., Fromm, M., Dempsey, P.,
et al. (1995). Interrelationship between substrates, and inhibitors of human
CYP3A, and P-gp. Pharm. Res. 16, 408–414. doi: 10.1023/A:10188778
03319
Komiya, I., Park, J. Y., Kamani, A., Ho, N. F. H., and Higuchi, W. I. (1980).
Quantitative mechanistic studies in simultaneous ﬂuid ﬂow and intestinal
absorption using steroids as model solutes. Int. J. Pharm. 4, 249–262. doi:
10.1016/0378-5173(80)90140-4
Krishna, D. R., and Koltz, U. (1994). Extrahepatic metabolism of drugs in
human. Clin. Pharmacokinet. 26, 144–160. doi: 10.2165/00003088-199426020-
00007
Lennernäs, H. (2007). Animal data: the contributions of the using chamber and
perfusion systems to predicting human oral drug delivery in vivo. Adv. Drug
Del. Rev. 59, 1103–1120. doi: 10.1016/j.addr.2007.06.016
Lipka, E., and Amidon, G. L. (1999). Setting bioequivalence requirements
for drug development based on preclinical data: optimizing oral drug
delivery systems. J. Control. Release 62, 41–49. doi: 10.1016/S0168-3659(99)
00022-X
Lo,M.W., Goldberg, M. R., Mccrea, J. B., Lu, H., Furtek, C. I., and Bjornsson, T. D.
(1995). Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and
its active metabolite EXP 3174 in humans. Clin. Pharmacol. Ther. 58, 641–649.
doi: 10.1016/0009-9236(95)90020-9
Miller, D. L., Schedl, H. P., Bouska, J., and Phillips, S. F. (1987). Food restriction
and recovery of non-absorbed indicators from the small intestine of the rat.
Digestion 38, 83–89. doi: 10.1159/000199576
Paine, M. F., Khalighi, M., and Fisher, J. M. (1997). Characterization of
interintestinal and intraintestinal variations in human CYP3Adependent
metabolism. J. Pharmacol. Exp. Ther. 283, 1552–1562.
Sinko, P. J., Leesman, G. D., and Amidon, G. L. (1991). Predicting fraction dose
absorbed in humans using a macroscopic mass balance approach. Pharm. Res.
8, 979–988. doi: 10.1023/A:1015892621261
Takahiro, I., katsuhisa, I., yayoi, H., Hiroaki, Y., and Jun, W. (2002). Metabolic
extraction of nifedipine during absorption from the small intestine. Drug.
Metab. Pharmacokin. 17, 546–553. doi: 10.2133/dmpk.17.546
Takano, M., Hasegawa, R., Fukuda, T., Yumoto, R., Nagai, J., and Murakami, T.
(1998). Interaction with P-glycoprotein and transport of erythromycin,
midazolam and ketoconazole in Caco-2 cells. Eur. J. Pharmacol. 358, 289–229.
doi: 10.1016/S0014-2999(98)00607-4
Thummel, K. E., Kunze, K. L., and Shen, D. D. (1997). Enzyme catalyzed processes
of ﬁrst-pass hepatic and intestinal drug extraction. Adv. Drug Del. Rev. 27,
99–127. doi: 10.1016/S0169-409X(97)00039-2
Trapani, G., Franco, M., Trapani, A., Lopedota, A., Latrofa, A., Gallucci, E.,
et al. (2004). Frog intestinal sac: a new in vitro method for the assessment
of intestinal permeability. J. Pharm. Sci. 93, 2909–2919. doi: 10.1002/jps.
20180
Tukker, J. J. (2000). “In vitro methods for the assessment of permeability,” in: Oral
Drug Absorption, eds J. B. Dressman and H. Lennernas (New York: Marcel
Dekker), 51–72.
Varma, M. V., and Panchagnula, R. (2005). Enhanced oral paclitaxel absorption
with vitamin E-TPGS: eﬀect on solubility and permeability in vitro, in
situ and in vivo. Eur. J. Pharm. Sci. 25,445–453. doi: 10.1016/j.ejps.2005.
04.003
Varma, M. V., Perumal, O. P., and Panchagnula, R. (2006). Functional role
of P-glycoprotein in limiting peroral drug absorption: optimizing drug
delivery. Curr. Opin. Chem. Biol. 10, 367–373. doi: 10.1016/j.cbpa.2006.
06.015
Verschraagen, M., Koks, C. H. W., Schellens, J. H. M., and Beijnen, J. H.
(1999). P-glycoprotein system as a determinant of drug interactions: the case
of digoxin–verapamil. Pharmacol. Res. 40, 301–306. doi: 10.1006/phrs.1999
.0535
Von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., and Kivisto,
K. T. (2004). Cytochrome P450 3A4 and P-glycoprotein expression in human
small intestinal enterocytes and hepatocytes: a comparative analysis in paired
tissue specimens. Clin. Pharmacol. Ther. 75, 172–183. doi: 10.1016/j.clpt.2003.
10.008
Yerasi, N., Devarakonda, K., and Vurimindi, H. (2010). Evaluation of frog as an
animal model to study the eﬀective permeability co-eﬃcient: application to
CYP3A4 substrates. Ann. Biol. Res. 1, 161–170.
Frontiers in Pharmacology | www.frontiersin.org 7 July 2015 | Volume 6 | Article 141
Yerasi et al. Frog intestinal perfusion to evaluate drug permeability
Yerasi, N., Vurimindi, H., and Devarakonda, K. (2015). Evaluation of frog as an
animal model to study the fraction of oral dose absorbed in humans. J. Bioequiv.
Availab. 7, 068–073. doi: 10.4172/jbb.1000217
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Yerasi, Vurimindi and Devarakonda. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 8 July 2015 | Volume 6 | Article 141
